Search General Info
Search Education
Search Partnering Companies
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
- Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests.
- Its first product is a blood test to significantly improve the early detection of liver cancer among high risk populations so that more patients can benefit from curative treatments.
- Its test is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.
- Mursla is currently running a multi-centre pilot study with four world leading universities across Europe and the support of global diagnostic leader, Roche Diagnostics.
- Mursla’s lead product is underpinned by seven patents, several publications and one of the best EV know-hows globally.
- Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category by UK government.
- Its first product is a blood test to significantly improve the early detection of liver cancer among high risk populations so that more patients can benefit from curative treatments.
- Its test is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.
- Mursla is currently running a multi-centre pilot study with four world leading universities across Europe and the support of global diagnostic leader, Roche Diagnostics.
- Mursla’s lead product is underpinned by seven patents, several publications and one of the best EV know-hows globally.
- Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category by UK government.
![](https://778c1607566f28c5e8fd-e6db6de54823ad7fd298e0f6ff75b72a.ssl.cf1.rackcdn.com/BIO_4121_EOISBJNL_508_MurslaBio-FileId-327179.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2019
Main Therapeutic Focus:
Diagnostics
Lead Product in Development:
ExoPheno-HCC: Liver cancer surveillance blood test
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-ArseneP.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved